CN114632101A - Cordyceps guangdongensis weight-losing lipid-lowering liver-protecting compound for treating obesity and related syndromes as well as preparation method and application thereof - Google Patents
Cordyceps guangdongensis weight-losing lipid-lowering liver-protecting compound for treating obesity and related syndromes as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN114632101A CN114632101A CN202210231735.XA CN202210231735A CN114632101A CN 114632101 A CN114632101 A CN 114632101A CN 202210231735 A CN202210231735 A CN 202210231735A CN 114632101 A CN114632101 A CN 114632101A
- Authority
- CN
- China
- Prior art keywords
- liver
- weight
- lipid
- parts
- reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a weight-reducing, lipid-lowering and liver-protecting compound of cordyceps guangdongensis for treating obesity and related syndromes as well as a preparation method and application thereof. Comprises Cordyceps guangdongensis fruiting body powder, conjugated linoleic acid glyceride, L-arabinose, navy bean, folium Nelumbinis powder, radix Puerariae, maltodextrin, instant green tea powder, microcrystalline cellulose, magnesium stearate and coating powder. The compound product of the invention comprises edible and medicinal fungi, plant source components and safe auxiliary materials, does not contain chemical substances with side effects, is nontoxic to animals and human beings, and has obvious effects of slimming, reducing blood fat and protecting liver.
Description
The technical field is as follows:
the invention belongs to the field of biological medicines, and particularly relates to a cordyceps guangdongensis weight-losing lipid-lowering liver-protecting compound for treating obesity and related syndromes as well as a preparation method and application thereof.
Background art:
at present, obesity is a common and serious public health problem, mainly caused by unbalanced and excessive accumulation of fat metabolism in vivo, and is a nutritional metabolic disorder disease which endangers human health. The excessive fat accumulated around and under the viscera can cause great harm to the health of human bodies, cause various diseases, such as hyperglycemia, type II diabetes, hyperlipidemia, hypertension, coronary heart disease and the like, and even further cause more serious diseases such as colon cancer, Alzheimer disease and the like. Compared with the common population, the obese people have abnormally increased total cholesterol and low-density lipoprotein cholesterol levels, and are more likely to suffer from cardiovascular diseases such as hypertension, hyperlipidemia, diabetes and the like. In obese people, an imbalance between triglyceride synthesis and transport results in a massive accumulation of triglycerides in the liver, while excessive fat accumulates in the liver, forming fatty liver and further affecting the health status. At present, more obese people lose weight by adopting a mode of combining exercise and medicines, and in the process, the problems of abnormal liver function, physiological discomfort and the like occur. Therefore, there is a great deal of interest in improving and treating obesity and its metabolic disorders more effectively and healthily.
A plurality of recent researches show that various plants, edible and medicinal fungi active ingredients and probiotics show good effects on reducing the weight and the pushing of fat tissues of obese mice, improving blood lipid parameters in serum and abnormal lipid metabolism in liver and the like. Cordyceps guangdongensis (Cordyceps guangdongensis) is a new resource food unique to China, belonging to genus Tolypocladium of Campylobacter of the family nematodiaceae, genus different from genus Ophiocordyceps (Ophiocordiceps) of the same family as Cordyceps (Ophiocordiceps sinensis), genus different from genus Cordyceps (Cordyceps) of the family different from Cordyceps (C.militaris). The Cordyceps guangdongensis fruiting body has effects of preventing and improving adenine-induced chronic renal failure and chronic bronchitis, reducing weight, relieving fatigue, resisting oxidation and virus, and improving immunity. The conjugated linoleic acid glyceride can block the conversion of carbon sugar heat, thereby achieving the effects of losing weight and reducing fat; the L-arabinose has the effects of controlling the increase of blood sugar in vivo, relieving the increase of body weight, reducing blood fat and the like by inhibiting the absorption of cane sugar and improving the abundance of beneficial microorganisms in intestinal tracts; the white kidney bean can block the starch decomposition in a receptor body to reduce the glucose absorption, thereby reducing the blood sugar rise, reducing the insulin secretion, reducing the fat synthesis and the like; nuciferine in the lotus leaf powder, puerarin in the radix puerariae and tea polyphenol in the green tea can also play roles in reducing weight, reducing hyperlipidemia and hyperglycemia, improving fatty liver and the like by regulating and controlling adipose tissues, blood lipid parameters, glycolipid metabolism and intestinal microorganisms.
The invention content is as follows:
the invention aims to provide a weight-losing, lipid-lowering and liver-protecting compound of cordyceps guangdongensis, which can treat obesity and related syndromes, and a preparation method and application thereof.
Theoretical basis:
the Cordyceps guangdongensis belongs to Tolypocladium of Ophiococcus of nematodiaceae, and its fruiting body has effects of relieving fatigue, resisting oxidation, preventing and improving adenine-induced renal failure, treating chronic bronchitis, improving immunity, reducing weight and reducing blood lipid.
The conjugated linoleic acid glyceride can block the conversion of carbon sugar heat, thereby achieving the effects of losing weight and reducing fat.
The L-arabinose can control the rise of blood sugar in vivo, relieve the rise of body weight, reduce blood fat and the like by inhibiting the absorption of sucrose and improving the abundance of beneficial microorganisms in intestinal tracts.
The white kidney bean can block the starch decomposition in a receptor body to reduce the glucose absorption, thereby reducing the blood sugar rise, reducing the insulin secretion, reducing the fat synthesis and the like.
Nuciferine in the powder has diuretic, weight reducing, and blood lipid reducing effects.
The puerarin in the kudzu root can obviously reduce the body weight of the nutritional obese rat and improve the lipid metabolism of the nutritional obese rat.
The active ingredients such as tea polyphenol, catechin and the like in the green tea can play roles of reducing weight, reducing hyperlipidemia and hyperglycemia, improving fatty liver and the like by regulating and controlling adipose tissues, blood fat parameters, glycolipid metabolism and intestinal microorganisms.
In order to realize the effects of losing weight and reducing fat, the invention implements the following technical scheme:
a weight-reducing, lipid-lowering and liver-protecting compound preparation of Cordyceps guangdongensis for treating obesity and related syndromes comprises fruiting body powder of Cordyceps guangdongensis (Cordyceps guangdongensis), conjugated linoleic acid glyceride, L-arabinose, navy bean, folium Nelumbinis powder, radix Puerariae, maltodextrin, instant green tea powder, microcrystalline cellulose, magnesium stearate and coating powder.
Preferably, the composition comprises the following components in parts by mass: 16 parts of cordyceps guangdongensis sporophore powder, 16 parts of conjugated linoleic acid glyceride, 16 parts of L-arabinose, 14 parts of white kidney bean powder, 11 parts of lotus leaf powder, 8 parts of kudzu vine root, 6 parts of maltodextrin, 5 parts of instant green tea powder, 4.3 parts of microcrystalline cellulose, 2 parts of magnesium stearate and 1.7 parts of coating powder.
The second purpose of the invention is to provide a preparation method of a cordyceps guangdongensis weight-losing lipid-lowering liver-protecting compound for treating obesity and related syndromes, which comprises the following steps: drying the Guangdong cordyceps sinensis sporocarp in an oven at 50-60 ℃, fully crushing in an ultralow temperature crusher at-20-15 ℃, weighing various raw material powder according to a proportion, and fully mixing uniformly to obtain the Guangdong cordyceps sinensis weight-reducing, lipid-lowering and liver-protecting compound for treating obesity and related syndromes. The invention gives full play to the synergistic effect among various components and shows good effects of losing weight, reducing fat and protecting liver. The product of the invention does not contain harmful chemical synthesis agent, is nontoxic to animals and human beings, and has obvious effects of slimming and reducing blood fat.
The obesity and related disorder metabolic syndrome in the invention comprise glucose tolerance, hyperlipidemia and fatty accumulation and lesion in liver.
Therefore, the cordyceps guangdongensis sporocarp powder and the plant source substance are mixed according to a certain proportion, the cordyceps guangdongensis weight-losing, lipid-lowering and liver-protecting compound for treating obesity and related syndromes is developed, and the functions of the formula in the aspects of relieving the weight and the weight gain rate of obese mice, improving the glucose tolerance capacity of the obese mice, reducing related indexes of hyperlipidemia in serum, relieving fat accumulation and damage degree in liver and the like are verified through a gavage high-fat induced obese mouse experiment, so that the cordyceps guangdongensis sporocarp powder has considerable economic value and good social benefit.
The weight-reducing, lipid-lowering and liver-protecting compound of the cordyceps guangdongensis is applied in detail as follows:
after SPF male C57BL/6J mice are fed with high-fat feed for 8 weeks, an obesity model is successfully constructed; the modeling group is randomly divided into a high-fat group and a Guangdong cordyceps weight-reducing and lipid-lowering group (formula group). The administration method is intragastric administration, and the dosage is 1.5g/kg/d once a day. The weight and food intake of the mice were weighed and recorded weekly, and samples were collected and assayed for blood glucose, adipose tissue, blood lipid and related indices in the liver after 14 weeks of continuous gavage.
The third purpose of the invention is to provide the application of the cordyceps guangdongensis weight-losing, lipid-lowering and liver-protecting compound in preparing the medicines for treating obesity and related syndromes.
Preferably, the obesity and related syndromes are degree of weight gain, adipose group weight, glucose intolerance, hyperlipidemia and degree of liver damage.
Preferably, the treatment of obesity and related syndromes is the enhancement of high fat induced glucose tolerance in obese mice; relieving the weight gain amplitude of high fat induced obese mice, reducing the accumulation of harmful adipose tissues and reducing the diameter of epididymal fat cells; reducing serum triglyceride, total cholesterol and low density lipoprotein cholesterol levels; reducing the activity of glutamic-pyruvic transaminase in serum and relieving the degree of liver injury; reduce the accumulation of lipid droplets in the liver and further reduce the accumulation of fat in the liver.
The invention has the following advantages:
(1) the compound product of the invention comprises edible and medicinal fungi, plant source components and safe auxiliary materials, does not contain chemical substances with side effects, is nontoxic to animals and human beings, and has obvious effects of slimming, reducing blood fat and protecting liver.
(2) The weight-losing, lipid-lowering and liver-protecting compound of cordyceps guangdongensis used by the invention obviously reduces the weight gain (26.51%), the relative weight gain rate (25.00%), the Lee's index (5.81%), the adipose tissue coefficient (41.55% and 19.28%) and the size of epididymis fat cells (25.28%) of a high-fat-induced obese mouse, and shows effective weight-losing efficacy.
(3) The weight-reducing, lipid-lowering and liver-protecting compound of cordyceps guangdongensis used by the invention obviously reduces the content of glucose in the blood of obese mice (14.93-21.86%), and improves the tolerance of the obese mice to the glucose.
(4) The weight-reducing, lipid-lowering and liver-protecting compound of cordyceps guangdongensis used by the invention obviously reduces the levels of triglyceride (21.87%), total cholesterol (32.91%) and low-density lipoprotein cholesterol (52.56%) in serum, thereby achieving the purpose of reducing blood fat.
(5) The weight-reducing, lipid-lowering and liver-protecting compound of cordyceps guangdongensis used in the invention obviously reduces the activity of glutamic-pyruvic transaminase (21.87%) in serum, and plays a role in protecting liver tissues.
(6) The weight-reducing, lipid-lowering and liver-protecting compound of cordyceps guangdongensis obviously reduces fat accumulation in the liver, reduces vacuolization lesion in the liver, and improves the liver coefficient (18.35%), thereby reducing the damage degree of fat to liver tissues.
Drawings
FIG. 1 shows that the weight-reducing, lipid-lowering and liver-protecting compound of Cordyceps guangdongensis of the invention can significantly improve the glucose tolerance of mice. Control group: normal diet group + gavage normal saline; high fat group: high fat diet group + gavage normal saline; the formula group is as follows: the high-fat diet and the cordyceps guangdongensis are compound for losing weight, reducing fat and protecting liver; lower case letters, very significant difference (P < 0.01).
FIG. 2 shows that the weight-losing, lipid-lowering and liver-protecting compound of Cordyceps guangdongensis of the invention can significantly reduce the weight (A), weight gain (B), weight gain rate (C) and Lee' coefficient (D) of a mouse. Control group: normal diet group + gavage normal saline; high fat group: high fat diet group + gavage normal saline; the formula group is as follows: the high-fat diet and the cordyceps guangdongensis are compound for losing weight, reducing fat and protecting liver; ns, no significant difference; significant difference (P < 0.05); significant differences (P < 0.01).
Fig. 3 shows the influence of the cordyceps guangdongensis weight-reducing, lipid-lowering and liver-protecting compound on the weight and the adipose tissue morphology (D) of the inguinal adipose tissue (A), the epididymis adipose tissue (B), the brown adipose tissue (C) of the mouse. Control group: normal diet group + gavage normal saline; high fat group: high fat diet group + gavage normal saline; the formula group is as follows: the high-fat diet and the cordyceps guangdongensis are compound for losing weight, reducing fat and protecting liver; ns, no significant difference; significant difference (P < 0.05); polar significance difference (P < 0.01).
FIG. 4 is a pathological section observation (x 200) of the weight-reducing, lipid-lowering and liver-protecting compound of Cordyceps guangdongensis in the invention on mouse epididymal fat cell HE staining. Control group: normal diet group + normal saline for intragastric administration; high fat group: high fat diet group + gavage normal saline; the formula group is as follows: the high-fat diet and the cordyceps guangdongensis are compound for losing weight, reducing fat and protecting liver; blue arrow, adipocyte diameter; red arrow, cytoplasmic fragmentation. FIG. 5 shows the effect of the compound preparation of Cordyceps guangdongensis in reducing weight, lowering lipid and protecting liver on triglyceride (A), total cholesterol (B) and low density lipoprotein cholesterol (C) in mice. Control group: normal diet group + gavage normal saline; high fat group: high fat diet group + gavage normal saline; the formula group is as follows: the high-fat diet and the cordyceps guangdongensis are compound for losing weight, reducing fat and protecting liver; ns, no significant difference; significant difference (P < 0.05); significant differences (P < 0.01).
FIG. 6 shows the effect of weight-reducing, lipid-lowering and liver-protecting compound of Cordyceps guangdongensis on relevant indexes of mouse liver. A, the weight-losing, lipid-lowering and liver-protecting compound of the cordyceps guangdongensis reduces the activity of glutamic-pyruvic transaminase in the serum of a mouse; b, the weight-reducing, lipid-lowering and liver-protecting compound of the cordyceps guangdongensis increases the liver coefficient of the obese mice; c, the cordyceps guangdongensis weight-reducing, lipid-lowering and liver-protecting compound influences the observation of a mouse liver HE staining pathological section (x 200); d, the weight-reducing, lipid-lowering and liver-protecting compound recipe of the cordyceps guangdongensis affects the observation of the mouse liver oil red staining pathological section (x 200). Control group: normal diet group + gavage normal saline; high fat group: high fat diet group + gavage normal saline; the formula group is as follows: the high-fat diet and the cordyceps guangdongensis are compound for losing weight, reducing fat and protecting liver; ns, no significant difference; significant difference (P < 0.05); significant difference in poles (P < 0.01); green arrows, tiny round fat vacuoles; yellow arrow, lipid droplet.
Detailed Description
The present invention will be described in detail with reference to specific examples. The experimental methods used in the examples are all conventional experimental methods unless otherwise specified. Materials, reagents and the like used in the examples are commercially available unless otherwise specified.
Guangdong Cordyceps fruiting body is provided by Guangdong Ke Huahuitai Biotechnology GmbH, conjugated linoleic acid glyceride and L-arabinose are purchased from Zhengzhou Baisanto health technology GmbH, white kidney bean, lotus leaf powder, radix Puerariae, maltodextrin and instant green tea powder are purchased from Shanxi Guosheng Biotechnology GmbH, microcrystalline cellulose and magnesium stearate are purchased from Henan sugar chest food GmbH, and coating powder is purchased from Jiangsu Xinyu pharmaceutical GmbH.
SPF-level male C57BL/6J mice were purchased from Shenzhen Seibano Gene technology, Inc., license number: SCXK (Jing) 2019-.
Example 1
The weight-losing, lipid-lowering and liver-protecting compound of cordyceps guangdongensis in the embodiment is composed of the following components in parts by weight: 16 parts of cordyceps guangdongensis fruiting body powder, 16 parts of conjugated linoleic acid glyceride, 16 parts of L-arabinose, 14 parts of white kidney bean powder, 11 parts of lotus leaf powder, 8 parts of kudzu vine root, 6 parts of maltodextrin, 5 parts of instant green tea powder, 4.3 parts of microcrystalline cellulose, 2 parts of magnesium stearate and 1.7 parts of coating powder.
The preparation method of the cordyceps guangdongensis weight-reducing, lipid-lowering and liver-protecting compound in the embodiment comprises the following steps:
(1) crushing: drying Cordyceps guangdongensis fruiting body in a rotary dryer at 55 deg.C, and pulverizing at-18 deg.C.
(2) Preparing powder: and (3) fully and uniformly mixing the cordyceps guangdongensis sporocarp powder and other purchased material powder according to the proportion, and packaging to obtain the cordyceps guangdongensis weight-reducing, lipid-lowering and liver-protecting compound.
Example 2
Grouping mice, modeling, regrouping and dosing, comprising the following steps:
1. grouping: the experimental animals are 90 SPF male C57BL/6J mice with the age of 7 weeks, the weight of the experimental animals is 19-21 g, the experimental animals are raised in the center of the institute of microbiology, Guangdong province academy of sciences, the temperature is 21 +/-2 ℃, the humidity is 55 +/-10%, and the light and the dark alternate for 12 hours. The 90 mice were divided into a control group with 3 replicates and a modeling group with 6 replicates each of 10 mice.
2. Molding: after 1 week of adaptive culture, the control group mice were fed with conventional feed (cooperative pharmaceutical biotechnology, llc, jiangsu), the model group was fed with high fat feed containing 60% fat (mass ratio: casein 200, l-cystine 3, sucrose 68.8, maltodextrin 12.5, cellulose 50, soybean oil 25, lard 245, mineral 10, vitamin 10, choline tartrate 2, potassium citrate monohydrate 16.5, calcium carbonate 5.5, calcium hydrogen phosphate dihydrate 13, energy ratio: protein 20, carbohydrate 20, fat 60; purchased from mr. hamarta mice, hi science and technology, etc.), the mice were fed with food and water freely during the model building, and the weight and food intake of the mice were weighed weekly and analyzed for significant difference. After the mice in the control group and the mice in the modeling group are continuously raised for 8 weeks, the body weight of the mice in the control group and the body weight of the mice in the modeling group are obviously different, and the obesity mice are successfully modeled.
3. Regrouping and dosing: the modeling components are a high-fat group and a formula group, the normal saline with the mass fraction of 0.8 percent is perfused into mice of the control group and the high-fat group according to the dose of 100 mu L/d, and the weight-reducing, lipid-lowering and liver-protecting compound solution of the cordyceps guangdongensis is perfused into the mice of the formula group according to the dose of 1.5 g/kg/d. Mice were fed and watered freely during dosing, and mouse body weight and food intake were recorded weekly. The body weights of the mice of the control group, the high fat group and the formula group are obviously different after the stomach filling for 14 weeks.
Example 3
Analysis of relevant indexes of weight reduction and lipid lowering and observation of adipose tissues and pathological sections of liver.
1. The weight-losing and lipid-lowering compound of Guangdong cordyceps sinensis improves the glucose tolerance of mice:
two weeks before sample collection, the mice are weaned for 12h, the tail tips are cut off at the positions of 0.2-0.3 mm of the tail tips of the mice by using a sterilization surgical scissors, the first drop of blood is discarded, and the blood glucose value is measured by a glucometer for 0 min. Perfusing glucose solution into stomach according to 1g/kg body weight, respectively collecting blood from tail tip for 15min, 30min, 60min, 90min and 120min, and measuring blood glucose value.
The results are shown in fig. 1, after 12 weeks of weight-reducing and lipid-lowering intervention of cordyceps guangdongensis, compared with the control mice, the glucose concentrations in blood of the mice in the high-fat group are respectively increased by 22.15%, 37.55%, 40.90%, 34.60% and 36.75% at 15min, 30min, 60min, 90min and 120 min; compared with the mice in the high-fat group, the concentration of glucose in blood of the mice in the formula group is obviously reduced (5.83-21.86 percent), which shows that the weight-reducing, lipid-lowering and liver-protecting compound of cordyceps guangdongensis effectively improves the glucose tolerance of the obese mice.
2. The weight-losing, lipid-lowering and liver-protecting compound of cordyceps guangdongensis has the following effects on the weight and related indexes of obese mice:
after fasting for 24 hours, the gavage 14-week mice were weighed, the length from the tip of the nose to the anus (body length) was measured, and the weight gain weight was calculated (final weight-adaptation 1)Weekly weight), rate of weight gain ═ final weight-weight adapted to 1 week/weight adapted to 1 week, Lee's index ═ weight1/3X 10/body length.
The results are shown in fig. 2, after 14 weeks of weight-reducing, lipid-lowering and liver-protecting compound intervention of cordyceps guangdongensis, compared with the control group of mice, the weight gain rate and the Lee's index of the high-fat group of mice are obviously increased, while the weight correlation coefficient of the formula group of mice is not obviously different from that of the control group. Compared with the mice in the high-fat group, the weight gain rate and the Lee' coefficient of the mice in the compound group are remarkably reduced by 26.51 percent, 25.00 percent and 5.81 percent respectively, which shows that the cordyceps guangdongensis weight-reducing, lipid-lowering and liver-protecting compound effectively relieves the weight gain of the obese mice induced by high-fat diet and plays a role in weight reduction.
3. The cordyceps guangdongensis weight-reducing, lipid-lowering and liver-protecting compound has the following effects on fat tissues of obese mice:
mice gavaged for 14 weeks were fasted for 24h with CO2After anesthesia, cervical dislocation was sacrificed, epididymal fat, brown fat and inguinal adipose tissue were taken, the recorded weight was weighed, and adipose tissue correlation coefficient (%). adipose tissue weight/mouse body weight was calculated.
According to the attached figure 3, after the cordyceps guangdongensis weight-reducing, lipid-lowering and liver-protecting compound intervention is carried out for 14 weeks, compared with a control group of mice, the epididymis fat coefficient and the inguinal fat coefficient of a high-fat group of mice are respectively increased by 53.51% and 39.28%, while only the inguinal fat coefficient of a formula group of mice is significantly increased by 24.78%; compared with the mice in the high fat group, the fat coefficient of the epididymis and the fat coefficient of the inguinal region of the mice in the formula group are obviously reduced by 41.55 percent and 19.28 percent respectively. In addition, the brown fat index of the control group mice is obviously higher than that of the high-fat group mice and the formula group mice, and the coefficient of the formula group mice is obviously higher than that of the high-fat group mice (the increase is 32.58%). From the form of fat group, the cordyceps guangdongensis weight-reducing, lipid-lowering and liver-protecting compound preparation reduces the length and width of epididymis fat and inguinal fat of obese mice and improves the width and state of brown fat group. The results show that the cordyceps guangdongensis weight-reducing, lipid-lowering and liver-protecting compound can effectively reduce redundant harmful fat and improve beneficial fat in high-fat-induced obese mice.
4. The cordyceps guangdongensis weight-reducing, lipid-lowering and liver-protecting compound influences the pathological section microscopic observation of the epididymis fat cells of the obese mice:
fixing epididymis adipose tissues in a 4% paraformaldehyde solution, dehydrating by adopting 80%, 90%, 95% and 100% ethanol in sequence, carrying out xylene transparent treatment, then carrying out paraffin embedding and slicing; the slices are sequentially decolorized in xylene for 20min, absolute ethyl alcohol for 5min, 75% ethyl alcohol for 5min and tap water, and then placed in hematoxylin for dyeing for 3-5 min; staining with eosin for 5min, sequentially decolorizing with anhydrous ethanol for 5min and xylene for 5min, and sealing with neutral gum. The changes in epididymal adipocytes were observed by electron microscopy (Leica, DM6/DMC 4500).
According to the attached figure 4, after the cordyceps guangdongensis compound intervention for 14 weeks, compared with the control group of mice, the epididymal fat cells of the high-fat group of mice have different sizes, more cell diameters are obviously increased (blue arrows), more cytoplasm rupture (red arrows) occurs, and the number of fat cells in the same visual field range is obviously reduced; and with high-fat group mice, the fat cells of the epididymis of the formula group mice are closely arranged, the cytoplasm is thin, a small amount of cytoplasm is broken, the cell diameter is obviously increased and reduced, and the fat cell number is obviously increased within the same visual field range. The results show that the weight-reducing, lipid-lowering and liver-protecting cordyceps guangdongensis compound can obviously reduce the diameter of epididymal fat cells and improve the stability of cytoplasm.
5. The weight-reducing, lipid-lowering and liver-protecting compound of the cordyceps guangdongensis reduces relevant indexes of blood fat in blood serum of mice:
the gavage 14 week mice were fasted for 24h and placed in a closed cage with CO2Anaesthetizing and taking blood from abdominal cavity, standing for 1h at room temperature, centrifuging at 3000rpm for 15min, and collecting upper layer serum. The change of the blood lipid index in serum is measured by a kit (purchased from Nanjing institute of biological engineering).
According to the attached figure 5, after the cordyceps guangdongensis compound intervention of weight reduction, lipid lowering and liver protection for 14 weeks, compared with a control mouse, the contents of triglyceride, total cholesterol and low density lipoprotein cholesterol in the serum of a high-fat group mouse are significantly different and are respectively increased by 17.56%, 42.61% and 37.51%, while the content of only total cholesterol in the serum of a formula group mouse is significantly increased by 14.45%; compared with mice in a high-fat group, the blood lipid indexes of 3 items in the serum of the mice in the formula group are obviously lower than those of the mice in the high-fat group, and are respectively reduced by 21.87%, 32.91% and 52.56%. The results show that the cordyceps guangdongensis weight-reducing, lipid-lowering and liver-protecting compound effectively reduces related indexes of hyperlipidemia in serum of high-fat-induced obese mice.
6. The weight-reducing, lipid-lowering and liver-protecting compound recipe of the cordyceps guangdongensis affects related indexes of the mouse liver and pathological section observation of the mouse liver:
liver tissues were taken and weighed, and liver correlation coefficient (%). liver tissue weight/mouse body weight was calculated. Liver was cut into two portions, one portion was soaked in 4% paraformaldehyde tissue fixative. Slicing the liver tissue, and observing an HE stained section in the synchronous step 4; simultaneously, carrying out oil red infection for 8-10 min (keeping out of the sun), taking out the slices, staying for 3s, immersing in 60% isopropanol for differentiation for 2 times for 3s and 5s, and sequentially immersing in pure water for immersion washing for 2 times, each for 10 s; staining with hematoxylin for 3-5 min, differentiating with 60% ethanol for 2-8 s, washing with distilled water for 10s, returning blue liquid to blue for 1s, washing with tap water for 10-15 s, and finally sealing with glycerol gelatin. Changes in lipid droplets in the liver were observed by electron microscopy (Leica, DM6/DMC 4500).
According to the attached figure 6A, compared with the control group of mice, the glutamic-pyruvic transaminase activity (related to the damage degree of liver cells) in the serum of the high-fat group of mice is remarkably increased by 47.85%, which indicates that the liver is damaged to a certain degree; compared with mice in a high-fat group, the activity of the alanine aminotransferase in the serum of the mice in the formula group is obviously reduced by 42.20 percent, and the liver damage degree of the obese mice is improved to a certain degree. The liver coefficient of the control group mice was significantly higher than that of the high-fat group and the formula group mice, and the liver coefficient of the formula group mice was significantly higher than that of the high-fat group mice by 18.35% (fig. 6B). The results of HE staining microscope observation show that the liver cells of the mice in the high fat group have steatosis, round fat vacuoles (green arrows) can be observed in cytoplasm, the area of the total lipid vacuoles is large, and the cell boundaries and the shapes are blurred; the liver cell liver cable of the mice in the formula group has clear structure, clear boundary and shape and regular structure, and has less lipid vacuole lesion (figure 6C). The results of oil red staining (fig. 6D) show that, compared with the control group mice, the livers of the high-fat group mice obviously contain more orange-red lipid droplets (yellow arrows), and more expanded air bubbles exist among cells; the liver of the mice in the formula group is light orange, and the expanded air bubbles among cells are less. The results show that the weight-reducing, lipid-lowering and liver-protecting compound of the cordyceps guangdongensis effectively weakens the damage degree of liver cells and relieves the accumulation of lipid (such as lipid drops) in the liver.
Therefore, the cordyceps guangdongensis weight-reducing, lipid-lowering and liver-protecting compound plays a positive role in relieving obesity, reducing blood fat and protecting liver, and the invention provides the application of the cordyceps guangdongensis weight-reducing, lipid-lowering and liver-protecting compound in weight reduction, lipid-lowering and liver protection.
The above list is only a few embodiments of the present invention. However, the present invention is not limited to the above embodiments, and many variations are possible. All modifications which can be derived or suggested by a person skilled in the art from the disclosure of the invention should be considered as within the scope of the invention.
Claims (10)
1. A weight-reducing, lipid-lowering and liver-protecting compound of cordyceps guangdongensis for treating obesity and related syndromes is characterized by comprising cordyceps guangdongensis sporophore powder, conjugated linoleic acid glyceride, L-arabinose, white kidney beans, lotus leaf powder, kudzu vine root, maltodextrin, instant green tea powder, microcrystalline cellulose, magnesium stearate and coating powder.
2. The weight-reducing, lipid-lowering and liver-protecting compound cordyceps guangdongensis according to claim 1 is characterized by comprising the following components in parts by mass: 16 parts of cordyceps guangdongensis fruiting body powder, 16 parts of conjugated linoleic acid glyceride, 16 parts of L-arabinose, 14 parts of white kidney bean powder, 11 parts of lotus leaf powder, 8 parts of kudzu vine root, 6 parts of maltodextrin, 5 parts of instant green tea powder, 4.3 parts of microcrystalline cellulose, 2 parts of magnesium stearate and 1.7 parts of coating powder.
3. The preparation method of the cordyceps guangdongensis weight-losing, lipid-lowering and liver-protecting compound for treating obesity and related syndromes according to claim 1 is characterized by comprising the following steps of: drying the Guangdong cordyceps sinensis sporocarp in an oven at 50-60 ℃, fully crushing in an ultralow temperature crusher at-20-15 ℃, weighing various raw material powder according to a proportion, and fully mixing uniformly to obtain the Guangdong cordyceps sinensis weight-reducing, lipid-lowering and liver-protecting compound for treating obesity and related syndromes.
4. The use of the cordyceps guangdongensis weight-reducing, lipid-lowering and liver-protecting compound of claim 1 or 2 in the preparation of a medicament for treating obesity and related syndromes.
5. The use according to claim 4, wherein the obesity and related syndromes are the degree of weight gain, adipose tissue weight, glucose intolerance, hyperlipidemia and degree of liver damage.
6. The use of claim 4, wherein said treatment of obesity and related syndromes is the enhancement of high fat induced glucose tolerance in obese mice.
7. The use of claim 4, wherein the treatment of obesity and related syndromes is the alleviation of the magnitude of body weight gain, the reduction of unwanted adipose tissue accumulation and the reduction of epididymal adipocyte diameter in high fat-induced obese mice.
8. The use according to claim 4, wherein said treatment of obesity and related syndromes is the reduction of serum levels of triglycerides, total cholesterol and low density lipoprotein cholesterol.
9. The use of claim 4, wherein the treatment of obesity and related syndromes is a reduction in serum glutamate pyruvate transaminase activity and a reduction in liver damage.
10. The use of claim 4, wherein the treatment of obesity and related syndromes is the reduction of lipid droplet accumulation in the liver, and thus the reduction of fat accumulation in the liver.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210231735.XA CN114632101B (en) | 2022-03-10 | 2022-03-10 | Cordyceps guangdongensis weight-losing lipid-lowering liver-protecting compound and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210231735.XA CN114632101B (en) | 2022-03-10 | 2022-03-10 | Cordyceps guangdongensis weight-losing lipid-lowering liver-protecting compound and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114632101A true CN114632101A (en) | 2022-06-17 |
| CN114632101B CN114632101B (en) | 2022-10-11 |
Family
ID=81948077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210231735.XA Active CN114632101B (en) | 2022-03-10 | 2022-03-10 | Cordyceps guangdongensis weight-losing lipid-lowering liver-protecting compound and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114632101B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115531478A (en) * | 2022-10-28 | 2022-12-30 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | Cordyceps guangdongensis blood sugar reducing formula for treating type 2 diabetes and related complications and preparation method thereof |
| CN115804872A (en) * | 2022-11-29 | 2023-03-17 | 上海交通大学 | Application of degradable magnesium-based metal wire in preparation of fat dissolving material |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557224A (en) * | 2004-02-12 | 2004-12-29 | 潘桂文 | Kudzu root tea beverage and its preparation method |
| CN101926891A (en) * | 2010-06-23 | 2010-12-29 | 北京康比特体育科技股份有限公司 | Composition for losing weight |
| CN102696813A (en) * | 2012-05-08 | 2012-10-03 | 安徽天方茶业（集团）有限公司 | Blood sugar-reducing instant green tea powder and preparation technology thereof |
| CN105146267A (en) * | 2015-08-24 | 2015-12-16 | 杭州娃哈哈科技有限公司 | Composition with weight losing function and application thereof |
| CN105434687A (en) * | 2014-09-29 | 2016-03-30 | 吴同忠 | Lotus leaf green tea for treating obesity |
| CN111346084A (en) * | 2020-03-20 | 2020-06-30 | 大连医诺生物股份有限公司 | Application of conjugated linoleic acid glyceride in preparation of product for treating high-fat diet-induced non-alcoholic fatty liver disease |
| CN113546097A (en) * | 2021-07-21 | 2021-10-26 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | Application of ethanol extract of cordyceps guangdongensis fruiting body in preparation of medicine for preventing obesity and hyperlipidemia |
-
2022
- 2022-03-10 CN CN202210231735.XA patent/CN114632101B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557224A (en) * | 2004-02-12 | 2004-12-29 | 潘桂文 | Kudzu root tea beverage and its preparation method |
| CN101926891A (en) * | 2010-06-23 | 2010-12-29 | 北京康比特体育科技股份有限公司 | Composition for losing weight |
| CN102696813A (en) * | 2012-05-08 | 2012-10-03 | 安徽天方茶业（集团）有限公司 | Blood sugar-reducing instant green tea powder and preparation technology thereof |
| CN105434687A (en) * | 2014-09-29 | 2016-03-30 | 吴同忠 | Lotus leaf green tea for treating obesity |
| CN105146267A (en) * | 2015-08-24 | 2015-12-16 | 杭州娃哈哈科技有限公司 | Composition with weight losing function and application thereof |
| CN111346084A (en) * | 2020-03-20 | 2020-06-30 | 大连医诺生物股份有限公司 | Application of conjugated linoleic acid glyceride in preparation of product for treating high-fat diet-induced non-alcoholic fatty liver disease |
| CN113546097A (en) * | 2021-07-21 | 2021-10-26 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | Application of ethanol extract of cordyceps guangdongensis fruiting body in preparation of medicine for preventing obesity and hyperlipidemia |
Non-Patent Citations (2)
| Title |
|---|
| 任凌燕等: "降糖袋泡茶对实验性糖尿病大鼠血糖及血脂的影响", 《实用中医药杂志》 * |
| 林群英等: "广东虫草与冬虫夏草及蛹虫草的成分比较", 《食用菌学报》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115531478A (en) * | 2022-10-28 | 2022-12-30 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | Cordyceps guangdongensis blood sugar reducing formula for treating type 2 diabetes and related complications and preparation method thereof |
| CN115531478B (en) * | 2022-10-28 | 2024-02-02 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | Cordyceps guangdong hypoglycemic pharmaceutical composition for treating type 2 diabetes and related complications and preparation method thereof |
| CN115804872A (en) * | 2022-11-29 | 2023-03-17 | 上海交通大学 | Application of degradable magnesium-based metal wire in preparation of fat dissolving material |
| CN115804872B (en) * | 2022-11-29 | 2024-02-27 | 上海交通大学 | Application of degradable magnesium-based metal wire in preparation of fat-soluble material |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114632101B (en) | 2022-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114632101B (en) | Cordyceps guangdongensis weight-losing lipid-lowering liver-protecting compound and preparation method and application thereof | |
| CN113546097B (en) | Application of ethanol extract of cordyceps guangdongensis fruiting body in preparation of medicine for preventing obesity and hyperlipidemia | |
| RU2697670C2 (en) | Pharmaceutical composition containing silybin and radix puerariae extract | |
| CN106573028A (en) | Composition for preventing and treating non-alcoholic fatty liver diseases | |
| Wu et al. | Hypoglycemic effect of okra aqueous extract on streptozotocin-induced diabetic rats | |
| CN106551398A (en) | A kind of anti-aging cream taste and preparation method thereof | |
| CN103734696B (en) | A kind of soft capsule and preparation method thereof improving immunity, protection internal organs | |
| CN111437310A (en) | Preparation method of high-activity oldenlandia diffusa total flavone and application of high-activity oldenlandia diffusa total flavone in liver peroxidation injury | |
| CN105168336A (en) | Natural medicine composition for adjusting diabetes immune and metabolism functions and preparation method of natural medicine composition | |
| CN114432337B (en) | Application of cordyceps guangdongensis fruiting body polysaccharide in preparation of medicine for treating and improving obesity and related diseases | |
| CN103766901A (en) | Application of andrographolide C to preparation of weight-losing food or medicine | |
| CN110876768A (en) | Traditional Chinese medicine formula, preparation method and application for losing weight, reducing fat and reducing blood fat | |
| CN105943617A (en) | Application of whole hemp extract in preparation of anti-hepatitis drugs | |
| CN109925445A (en) | Anoectochilus causes the application in acute liver drug in preparation prevention and/or treatment D-Gal | |
| CN109566806A (en) | It is a kind of for promoting the sargassum fusifome extracting solution of selenium-enriched vine tea health-care effect | |
| CN113694104B (en) | Traditional Chinese medicine composition with protection effect on chemical liver injury and liver regeneration promotion function, preparation method and application thereof | |
| CN111632082B (en) | American ginseng and hovenia dulcis thunb composition and application thereof in preparing medicine for preventing and treating alcoholic liver injury | |
| CN107088206A (en) | A kind of preparation method and applications of mulberry bark extract | |
| CN105535866A (en) | Medicine for treating hyperlipidemia and preparation method thereof | |
| CN112655967A (en) | Artemisia sphaerocephala essential oil microcapsule taking purslane extract as wall material and preparation method thereof | |
| CN106942439B (en) | Cyclocarya paliurus and guava leaf blood glucose reducing tea and preparation method and application thereof | |
| CN111346102A (en) | Application of baicalin in treating and preventing non-alcoholic fatty liver disease | |
| CN115531478B (en) | Cordyceps guangdong hypoglycemic pharmaceutical composition for treating type 2 diabetes and related complications and preparation method thereof | |
| CN114712481B (en) | Composite plant source polypeptide and preparation method and application thereof | |
| CN105963356A (en) | Anti-hepatitis medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |